Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia

Autor: Anne E Holland, Sally de Boer, Leonie J Jones, Christopher Grainge, Margaret Wilsher, Peter Hopkins, Ian Glaspole, Sally Chapman, Paul N. Reynolds, Helen Whitford, Tamera J. Corte, Helen E. Jo, Gregory J. Keir, Daniel C. Chambers, David Beatson, Yuben Moodley, Nicole S L Goh, Lauren K. Troy
Rok vydání: 2017
Předmět:
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Indoles
Pyridones
medicine.medical_treatment
Population
Comorbidity
03 medical and health sciences
Idiopathic pulmonary fibrosis
chemistry.chemical_compound
0302 clinical medicine
Pulmonary Medicine
Humans
Medicine
Pulmonary rehabilitation
030212 general & internal medicine
education
Intensive care medicine
Societies
Medical
Randomized Controlled Trials as Topic
education.field_of_study
Evidence-Based Medicine
Lung
business.industry
Anti-Inflammatory Agents
Non-Steroidal
Australia
Interstitial lung disease
Pirfenidone
respiratory system
medicine.disease
Idiopathic Pulmonary Fibrosis
humanities
respiratory tract diseases
Clinical trial
medicine.anatomical_structure
030228 respiratory system
chemistry
Disease Progression
Physical therapy
Nintedanib
business
New Zealand
medicine.drug
Zdroj: Respirology. 22:1436-1458
ISSN: 1323-7799
DOI: 10.1111/resp.13146
Popis: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2–5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval. This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum and treatment of co-morbid conditions. The utility of non-pharmacological therapies including pulmonary rehabilitation, oxygen as well as symptom management thought to be important in the holistic care of IPF patients are also discussed.
Databáze: OpenAIRE
Externí odkaz: